Head-to-head dispatch
HealthRX vs Omada Health
Two GLP-1 providers, one scorecard. Both are graded on the same six Desk Score dimensions — here is how they stack up, and which one fits you.
Desk Score
A LegitScript-certified compounding platform whose pricing page prints every plan's total, per-month rate and renewal price — and whose renewals are cheaper than sign-up.
$190/mo month-to-month ($149 first month on Subscribe & Save, renews at $165) · $99/mo on a 12-month prepay ($1,188) sema · $239/mo month-to-month ($193 first month on Subscribe & Save, renews at $214) · $179/mo on a 12-month prepay ($2,148) tirz · Verified August 29, 2026
Marked down on: Compounded medications are not FDA-approved
Desk Score
Omada Health is a virtual care company offering behavior-change programs for weight health, diabetes and hypertension, distributed through employers and health plans.
Marked down on: Core program distributed via employers and health plans, limited cash-pay
HealthRX takes this head-to-head with the higher Desk Score, 86/100 (B) against 48/100 (C) for Omada Health. Omada Health still holds its ground where its strengths line up with yours.
Desk Score, dimension by dimension
Same six measured dimensions for both. The red flag marks the stronger side. See the methodology.
HealthRX
86/100
B
Omada Health
48/100
C
Price transparency
State access
Molecule range
Onboarding speed
Support responsiveness
Licensing & trust
The spec sheet
| Field | HealthRX | Omada Health |
|---|---|---|
| Semaglutide | $190/mo month-to-month ($149 first month on Subscribe & Save, renews at $165) · $99/mo on a 12-month prepay ($1,188) | Not listed on Omada Health's site (checked July 26, 2026) |
| Tirzepatide | $239/mo month-to-month ($193 first month on Subscribe & Save, renews at $214) · $179/mo on a 12-month prepay ($2,148) | Not listed on Omada Health's site (checked July 26, 2026) |
| Coverage | All 50 states | Not listed on Omada Health's site (checked July 26, 2026) |
| Brand-name | Compounded only | Compounded only |
| Oral option | Injectable only | Injectable only |
| Best for | Patients who want a certified program with every plan price and renewal in one table, and a full refund if a provider does not approve them. | Plan members wanting behavior-change support plus 50-state GLP-1 prescribing. |
| Desk Score | 86/100B | 48/100C |
The verdict
Desk pick — HealthRXHealthRX takes this head-to-head with the higher Desk Score, 86/100 (B) against 48/100 (C) for Omada Health. Omada Health still holds its ground where its strengths line up with yours.
Choose HealthRX if…
Patients who want a certified program with every plan price and renewal in one table, and a full refund if a provider does not approve them.
$190/mo month-to-month ($149 first month on Subscribe & Save, renews at $165) · $99/mo on a 12-month prepay ($1,188) sema · $239/mo month-to-month ($193 first month on Subscribe & Save, renews at $214) · $179/mo on a 12-month prepay ($2,148) tirz · All 50 states
Choose Omada Health if…
Plan members wanting behavior-change support plus 50-state GLP-1 prescribing.
Assume any provider we list may compensate us — we may earn a referral commission at no extra cost to you, and what we file on a provider reads the same either way. Read full breakdowns: HealthRX · Omada Health.
Also here
CoreAge Rx tops every dispatch at 94/100
Whichever of these two you lean toward, the Desk's #1-rated provider outscores them both. The Desk's top dispatch: one price at every dose, both molecules, all 50 states — but the $99 and $149 figures are 12-month plans paid up front, not a monthly bill.
More head-to-heads
- CoreAge Rx vs HealthRX
- CoreAge Rx vs Omada Health
- HealthRX vs Trimi
- Omada Health vs Ondra Health
- Elara Health and Wellness vs HealthRX
- Invigor Medical vs Omada Health
Or see the full comparison hub and the complete ranking.
Pricing and verification reflect each provider's public disclosures at last scoring; the Desk Score is our editorial judgment per the methodology. Prices change — confirm on each provider's own site. Not medical advice; see our disclosure.